Back to Search
MATTHEW FRALEY, MD
MD
Cardiovascular Disease Physician
NPI: 1326187352IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
036-123183(IL)2004021586(MO)
CMS Specialties
PrimaryCARDIOVASCULAR DISEASE (CARDIOLOGY)
Education
SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE
Class of 2001
Research & Publications (20)
Positive allosteric modulators of the metabotropic glutamate receptor 2 for the treatment of schizophrenia.
PMID 19552508·Expert Opin Ther Pat·2009
6-review
Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
PMID 19155174·Bioorg Med Chem Lett·2009
8-other
Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-n-[(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer.
PMID 18578472·J Med Chem·2008
8-other
Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase.
PMID 17900896·Bioorg Med Chem Lett·2007
8-other
Kinesin spindle protein (KSP) inhibitors. Part 7: Design and synthesis of 3,3-disubstituted dihydropyrazolobenzoxazines as potent inhibitors of the mitotic kinesin KSP.
PMID 17804233·Bioorg Med Chem Lett·2007
7-preclinical
Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
PMID 17804227·Bioorg Med Chem Lett·2007
8-other
Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.
PMID 17761419·Bioorg Med Chem Lett·2007
8-other
Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by beta-fluorination to overcome cellular efflux by P-glycoprotein.
PMID 17395460·Bioorg Med Chem Lett·2007
8-other
An inhibitor of the kinesin spindle protein activates the intrinsic apoptotic pathway independently of p53 and de novo protein synthesis.
PMID 17101792·Mol Cell Biol·2007
8-other
Development of 6-substituted indolylquinolinones as potent Chek1 kinase inhibitors.
PMID 16990002·Bioorg Med Chem Lett·2006
7-preclinical
3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.
PMID 16978863·Bioorg Med Chem Lett·2006
8-other
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP.
PMID 16439123·Bioorg Med Chem Lett·2006
8-other
Kinesin spindle protein (KSP) inhibitors. Part 3: synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility.
PMID 16439122·Bioorg Med Chem Lett·2006
7-preclinical
Design and synthesis of 3,7-diarylimidazopyridines as inhibitors of the VEGF-receptor KDR.
PMID 15012992·Bioorg Med Chem Lett·2004
8-other
A novel orally bioavailable inhibitor of kinase insert domain-containing receptor induces antiangiogenic effects and prevents tumor growth in vivo.
PMID 14744794·Cancer Res·2004
7-preclinical
Optimization of the indolyl quinolinone class of KDR (VEGFR-2) kinase inhibitors: effects of 5-amido- and 5-sulphonamido-indolyl groups on pharmacokinetics and hERG binding.
PMID 14698157·Bioorg Med Chem Lett·2004
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 1225 GRAHAM RD STE C-2310
FLORISSANT, MO 63031 - Phone
- (618) 228-4215
Quick Facts
- NPI
- 1326187352
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 2
- Years in Practice
- 25
- Publications
- 20
Are you this provider?
Claim Your Profile